Where Are The Novel Products From Big Pharma?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Specialty firms again in 2010 dominated new molecular entity and novel biologic approvals, suggesting that the much-discussed pipeline drought facing big pharma has yet to improve.